ARVINAS
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.
ARVINAS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.arvinas.com
Total Employee:
251+
Status:
Active
Contact:
(203)535-1456
Email Addresses:
[email protected]
Total Funding:
461.6 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 Microsoft Akamai Hosted
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Arvinas
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Arvinas
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Arvinas
ArrowMark Partners
ArrowMark Partners investment in Post-IPO Equity - Arvinas
Citadel Global Equities
Citadel Global Equities investment in Post-IPO Equity - Arvinas
BB Biotech Ventures
BB Biotech Ventures investment in Post-IPO Equity - Arvinas
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Arvinas
RTW Investments
RTW Investments investment in Post-IPO Equity - Arvinas
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Arvinas
Avidity Partners
Avidity Partners investment in Post-IPO Equity - Arvinas
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-02-27 | Oerth Bio | Arvinas investment in Corporate Round - Oerth Bio | 55 M USD |
Key Employee Changes
Official Site Inspections
http://www.arvinas.com Semrush global rank: 1.86 M Semrush visits lastest month: 11.81 K
- Host name: ec2-34-201-227-227.compute-1.amazonaws.com
- IP address: 34.201.227.227
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Arvinas"
About - Arvinas
You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any …See details»
Arvinas - Crunchbase Company Profile & Funding
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of …See details»
Final Annual Report 2022 - Arvinas
Apr 28, 2023 Our ultimate success as an organization is inherently tied to the communities in which we work, live, and serve. With this in mind, we took steps in 2022 to engage with the …See details»
Arvinas - LinkedIn
Arvinas | 23,143 followers on LinkedIn. Leading the way in targeted protein degradation therapeutics | Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of ...See details»
Arvinas Announces Changes to its Board of Directors
“It is an honor to be part of an organization that is at the forefront of pioneering targeted protein degradation therapies and revolutionizing the field of medicine,” added Dr. Agarwal. “I look …See details»
Bringing a Business Brain to Biotech - Arvinas
A key component to Arvinas’ early business plan was bringing pharma validation to the new field of protein degradation, and to build critical mass around the organization. By the time of …See details»
Arvinas - Funding, Financials, Valuation & Investors - Crunchbase
Arvinas is registered under the ticker NASDAQ:ARVN . Their stock opened with $16.00 in its Sep 26, 2018 IPO. Arvinas is funded by 21 investors. Great Point Partners and EcoR1 Capital are …See details»
Arvinas, Inc. (ARVN) Company Profile & Overview - Stock Analysis
Nov 19, 2024 Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The …See details»
Arvinas Company Profile - Office Locations, Competitors ... - Craft
Arvinas has 5 employees at their 1 location and $78.5 m in annual revenue in FY 2023. See insights on Arvinas including office locations, competitors, revenue, financials, executives, …See details»
Arvinas to Present at Piper Sandler 36th Annual Healthcare …
4 days ago Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Contacts. Investors: Jeff Boyle …See details»
Arvinas Enters into a Transaction with Novartis, including a Global ...
Apr 11, 2024 – Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement …See details»
Giving Back - Arvinas
At Arvinas, we’re committed to giving back to both the patient communities we aim to serve and the communities in which we live. Giving back through volunteer groups, nonprofit …See details»
Amid $350M fundraise, ‘promising’ clinical trial data, Arvinas sets ...
Jan 22, 2024 At the 2023 San Antonio Breast Cancer Symposium in December, Arvinas and Pfizer announced interim data from a phase 1b trial of Vepdegestrant, an estrogen receptor …See details»
Arvinas Gives Back to Local Greater New Haven Community in …
Oct 18, 2023 Save the Sound Beach & Park Cleanups: Over 70 Arvinas team members gathered at New Haven’s Long Wharf Beach and Lighthouse Point Park to join Save the …See details»
Arvinas and Pfizer Announce Global Collaboration to Develop and ...
Jul 22, 2021 NEW HAVEN, Conn. and NEW YORK – July 22, 2021 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced a global collaboration to develop and …See details»
Breaking Barriers in Biotech: The Arvinas Founding Story
In some ways, the idea behind Arvinas began with a failed venture capital (VC) pitch attempt. It was 20 years ago, and Arvinas founder, Craig Crews, was trying to start his first company. …See details»
Arvinas Reports Third Quarter 2024 Financial Results and ... - Nasdaq
Sep 30, 2024 --Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third …See details»
Arvinas (ARVN) Earnings Date and Reports 2025 - MarketBeat
3 days ago With a trailing EPS of -$4.67, Arvinas' earnings are expected to decrease next year, from ($3.24) to ($4.43) per share. Conference Call Transcript; Conference Call Audio; SEC 10 …See details»
Patients - Arvinas
At Arvinas, we are committed to patients, their families, and their caregivers, as we aim to deliver transformational treatments through scientific innovation for life-threatening and life-altering …See details»